PTC Therapeutics (PTCT) PT Lowered to $42 at RBC Capital
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts PTCT Hot Sheet
Price: $59.97 -6.97%
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Rating Summary:
17 Buy, 6 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 50 | New: 9
Join SI Premium – FREE
RBC Capital analyst Brian Abrahams lowered the price target on PTC Therapeutics (NASDAQ: PTCT) to $42.00 (from $45.00) while maintaining a Sector Perform rating.
You May Also Be Interested In
- PTC Therapeutics (PTCT) PT Raised to $95 at TD Cowen
- Veralto Corp. (VLTO) PT Raised to $135 at Jefferies, 'Accelerating Core Growth into 2027'
- Eli Lilly (LLY) PT Raised to $1,600 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
